Avidea has ongoing partnerships with industry, academic and government labs. Together, we are advancing the next generation of immunotherapies.
Avidea’s PDC platforms can be adapted for various biomedical applications. This enables exciting opportunities to collaborate on the development of new products or advance existing candidates.
Our validated approach ensures rapid identification of promising leads and a facile development path. In short, we use combinatorial synthesis and in vivo screening to rapidly identify promising leads. We then leverage our established manufacturing infrastructure and know-how to ensure a smooth development path.